Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
langerin-targeted mRNA lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- Cutanos
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intradermal, Topical
01
Overview
Langerin-targeted mRNA lipid nanoparticles (LNPs) are an experimental vaccine and therapeutic platform developed by Cutanos (based on research from the University of Vienna and Max Planck Institute). The system, known as the Langerhans Cell-Targeted Delivery System (LC-TDS), utilizes a glycomimetic small-molecule ligand to specifically target Langerin (CD207), a C-type lectin receptor expressed on skin-resident Langerhans cells. By selectively delivering antigen-encoding mRNA to these professional antigen-presenting cells in the epidermis, the platform enhances antigen translation and induces robust systemic CD8+ and CD4+ T-cell responses. This targeted approach allows for significant dose-sparing and potentially reduces systemic side effects by avoiding off-target accumulation in the liver, making it a promising candidate for both cancer immunotherapy and infectious disease vaccines.
- Other names
- LC-targeted LNPslangerin-specific mRNA LNPsLangerhans cell-targeted mRNA delivery system
02
Targets
CD207 (Langerin)
Beyond the preview
Go deeper on langerin-targeted mRNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on langerin-targeted mRNA lipid nanoparticles.